Allergy / Dermatology

Antibody profiling for precision dermatology

A single blood sample, interrogated for the full antibody and autoantibody repertoire, to resolve disease endotypes, illuminate mechanism of action, quantify pharmacodynamic response, and guide rational therapy selection.

The clinical rationale

Dermatological disease is etiologically heterogeneous, spanning adaptive autoimmunity, barrier dysfunction with allergen sensitization, and dysbiosis-driven inflammation, frequently co-occurring in one patient. A shared diagnosis rarely implies a shared mechanism.
Multiplexed serology resolves this heterogeneity from a single blood draw, quantifying autoreactivity to self antigens together with humoral responses to microbial and allergenic exposures.
The translational payoff is concrete: molecular diagnosis and endotyping, mechanistic insight, pharmacodynamic monitoring, and a rational basis for therapy selection. [4]

DISEASE AXIS	PRIMARY DRIVER	ROLE OF MICROBIOME / ALLERGENS	EXAMPLES
Autoimmune / autoinflammatory	Adaptive immunity targets self-antigens	Secondary: may precipitate flares	Cutaneous lupus (CLE), systemic sclerosis (diffuse cutaneous), vitiligo, pemphigus, alopecia areata, autoimmune (type IIb) CSU
Barrier-driven / atopic	Barrier defect enables allergen and microbial ingress	Major: dysbiosis and pathogen overgrowth sustain inflammation	Atopic dermatitis, contact dermatitis
Systemic mixed-axis	Internally driven hyper-immune response, gut-skin axis	Modulatory: gut dysbiosis aggravates cutaneous disease	Psoriasis, hidradenitis suppurativa, CSU

Autoreactivity is a recurring thread

Autoreactivity recurs across the dermatological spectrum: pan-disease markers such as antinuclear antibodies (ANA) and anti-thyroid-peroxidase (anti-TPO) are prevalent, whereas disease-restricted specificities remain incompletely mapped, as in hidradenitis suppurativa.
The iI2K content already encompasses established diagnostic autoantigens. In idiopathic inflammatory myopathy, myositis-specific autoantigens have been mechanistically linked to TLR7/8-dependent type I interferon induction, exemplifying how a reactivity signature reports on pathogenesis rather than mere association. This Alden-led study was selected for the journal’s Clinical Connections clinical highlight. [1,6]
Interpreting the composite signature, rather than a single analyte, identifies the patients whose disease is driven through a defined pathway, those most likely to benefit from a mechanism-matched therapeutic.

Effector function is isotype-determined

The same epitope engaged by different heavy-chain classes elicits distinct biology, and the classes span several orders of magnitude in serum abundance.

ISOTYPE	HEAVY CHAIN	SERUM CONCENTRATION	SHARE	HALF-LIFE	MAIN FUNCTION
IgG	γ	~10 mg/mL	~80%	23 d	Dominant systemic antibody; neutralization, opsonization, complement fixation; immune memory
IgA	α	~2 to 3 mg/mL	~13%	5.8 d	Mucosal immunity; mucus, saliva, tears
IgM	μ	~1.5 mg/mL	~6%	5.1 d	Early response; pentameric complement fixation; B-cell receptor
IgE	ε	~50 to 300 ng/mL	<0.001%	1.3 d	Allergy and anti-parasite; arms mast cells and basophils via FcεRI

CSU: two resolvable autoimmune endotypes

CSU resolves into type I (autoallergic), mediated by IgE autoantibodies to autoallergens that cross-link FcεRI, and type IIb (autoimmune), mediated by IgG autoantibodies to FcεRI or receptor-bound IgE, with divergent serology, disease course, and therapeutic responsiveness. [5]
Endotype discrimination is contingent on reliable IgE autoantibody detection. Given the four-to five-log excess of IgG over IgE, Alden employs a dedicated IgE-enrichment step that renders type I profiling analytically tractable where conventional assays fail. [3]
In the Novartis remibrutinib (REMIX-1/2) program, a composite IgE and IgG autoantibody panel discriminated CSU from healthy controls with high sensitivity and specificity and supports endotype-level stratification in trials. [2]

The strategic payoff: one array, every program, one compounding database

Why this compounds across a development portfolio

A single standardized iI2K array is deployed across autoimmune, oncology, allergy, and infectious-disease programs. A new dermatology study therefore inherits a validated, cross-indication method rather than a bespoke assay.
Each program accrues to a harmonized, cross-disease and cross-subgroup compendium of antibody reactivities. Shared antigen content and shared control cohorts mean every subsequent study begins from established benchmarks.
This is Alden’s differentiator: not an isolated assay but a comparable, compounding readout that converts one blood sample into diagnosis, mechanism, pharmacodynamics, and therapy selection across an entire portfolio.

References

Wu Y, et al. TLR7/8 activation by RNA-containing immune complexes in myositis. Arthritis & Rheumatology. 2025;77(2):190-201.
Saini S, Metz M, Hide M, … Budde P, Bräutigam M, Zucht HD, et al. A novel panel of autoantibodies may assist in the molecular diagnosis of CSU. J Allergy Clin Immunol. 2026;157(2 Suppl):AB8 (AAAAI 2026, Abstract 022). https://www.jacionline.org/article/S0091-6749(25)01211-4/fulltext
Karachaliou C-E, Livaniou E. Immunochemical determination of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria: a narrative review. Antibodies. 2026;15(2):44. doi:10.3390/antib15030044.
Biomarkers and treatment selection in dermatology: Dermatology Times (EADV plenary); ReproCell/Biopta.
Maurer M, Eyerich K, Eyerich S, et al. Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. Int Arch Allergy Immunol. 2020;181(5):321-333. doi:10.1159/000507218.
Clinical Connections. Arthritis & Rheumatology. 2025;77 (highlight of ref [1]). doi:10.1002/art.42874.

Figures are original Alden Scientific Immune artwork.